SG11201807472TA - Amanitin conjugates - Google Patents

Amanitin conjugates

Info

Publication number
SG11201807472TA
SG11201807472TA SG11201807472TA SG11201807472TA SG11201807472TA SG 11201807472T A SG11201807472T A SG 11201807472TA SG 11201807472T A SG11201807472T A SG 11201807472TA SG 11201807472T A SG11201807472T A SG 11201807472TA SG 11201807472T A SG11201807472T A SG 11201807472TA
Authority
SG
Singapore
Prior art keywords
international
pct
liehwiese
hilffelsheim
amatoxin
Prior art date
Application number
SG11201807472TA
Inventor
Christian Lutz
Jan Anderl
CHRISTOPH MüLLER
Werner Simon
Susanne Werner-Simon
Torsten Hechler
Michael Kulke
Original Assignee
Heidelberg Pharma Res Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Res Gmbh filed Critical Heidelberg Pharma Res Gmbh
Publication of SG11201807472TA publication Critical patent/SG11201807472TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)

Abstract

bete-An40. Amenin 30.2105 40Y., W O 20 17 / 149077 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/149077 Al 8 September 2017 (08.09.2017) WIPO I PCT (51) International Patent Classification: A61K 47/68 (2017.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2017/054911 (22) International Filing Date: 2 March 2017 (02.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16000511.2 3 March 2016 (03.03.2016) EP (71) Applicant: HEIDELBERG PHARMA GMBH [DE/DE]; Schriesheimer Strasse 101, 68526 Ladenburg (DE). (72) Inventors: LUTZ, Christian; Am Feldrain 36, 69469 Weinheim (DE). ANDERL, Jan; Fichtenstrasse 7, 64397 Modautal (DE). MULLER, Christoph; Mumbacher Str. 38, 69488 Birkenau (DE). SIMON, Werner; In der Liehwiese 29, 55595 Hilffelsheim (DE). WERNER-SI- MON, Susanne; In der Liehwiese 29, 55595 Hilffelsheim (DE). HECHLER, Torsten; Milhlbergweg 24, 64686 Lautertal (DE). KULKE, Michael; Egellstrasse 17, 67071 Ludwigshafen (DE). (74) Agent: WALLINGER RICKER SCHLOTTER TOST- MANN PATENT- UND RECHTSANWALTE, PART- NERSCHAFT MBB; Dr. Mathias Ricker, Zweibriicken- strasse 5-7, 80331 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: AMANITIN CONJUGATES FIGURE 7 (57) : The invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6'-deoxy posi- tion; and (ii) an amino acid 8 with an S-deoxy position; (b) a target-binding moiety; and (c) optionally a linker linking said amatoxin and said target-binding moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate. 11111111111111011101111111111101011111011101011111111011111111111111111111111110111111
SG11201807472TA 2016-03-03 2017-03-02 Amanitin conjugates SG11201807472TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16000511.2A EP3222292A1 (en) 2016-03-03 2016-03-03 Amanitin conjugates
PCT/EP2017/054911 WO2017149077A1 (en) 2016-03-03 2017-03-02 Amanitin conjugates

Publications (1)

Publication Number Publication Date
SG11201807472TA true SG11201807472TA (en) 2018-09-27

Family

ID=55456549

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913942SA SG10201913942SA (en) 2016-03-03 2017-03-02 Amanitin conjugates
SG11201807472TA SG11201807472TA (en) 2016-03-03 2017-03-02 Amanitin conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913942SA SG10201913942SA (en) 2016-03-03 2017-03-02 Amanitin conjugates

Country Status (25)

Country Link
US (2) US11590238B2 (en)
EP (2) EP3222292A1 (en)
JP (2) JP7084313B2 (en)
KR (1) KR102466933B1 (en)
CN (1) CN108778341B (en)
AU (1) AU2017228020B2 (en)
BR (1) BR112018067615A2 (en)
CA (1) CA3015138A1 (en)
CL (1) CL2018002502A1 (en)
CO (1) CO2018009533A2 (en)
DK (1) DK3423104T5 (en)
ES (1) ES2925006T3 (en)
HR (1) HRP20220948T1 (en)
HU (1) HUE059360T2 (en)
LT (1) LT3423104T (en)
MX (1) MX2018010247A (en)
NZ (1) NZ745508A (en)
PL (1) PL3423104T3 (en)
PT (1) PT3423104T (en)
RS (1) RS63451B1 (en)
RU (1) RU2753416C2 (en)
SG (2) SG10201913942SA (en)
SI (1) SI3423104T1 (en)
WO (1) WO2017149077A1 (en)
ZA (1) ZA201805336B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471772A4 (en) 2016-06-17 2020-03-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
CN110099698B (en) 2016-12-23 2023-02-17 海德堡医药研究有限责任公司 Amanitin antibody conjugates
CN110461876B (en) 2017-01-20 2024-05-17 海德堡医药研究有限责任公司 Compositions and methods for depleting cd137+ cells
EP3738608A4 (en) * 2017-08-18 2021-12-08 Sichuan Baili Pharm Co. Ltd Non-natural amatoxin-type antibody conjugate
KR20190043031A (en) * 2017-10-17 2019-04-25 한국화학연구원 Amatoxin derivatives and methods for their preparation
WO2019090242A1 (en) * 2017-11-04 2019-05-09 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
CN111867621A (en) * 2018-01-18 2020-10-30 美真达治疗公司 Compositions and methods for depleting CD134+ cells
JP2021521202A (en) * 2018-04-13 2021-08-26 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング Targeted amatoxin complex for the treatment of solid tumors
EP3801635A4 (en) * 2018-06-07 2022-04-06 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (adcs)
WO2020023556A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy
WO2020127968A1 (en) 2018-12-20 2020-06-25 Marino Stephen F Protein-drug conjugate comprising a monomeric form of proteinase 3
US20200407440A1 (en) 2019-04-24 2020-12-31 Magenta Therapeutics, Inc. Amatoxin antibody-drug conjugates and uses thereof
KR20220011640A (en) 2019-05-23 2022-01-28 하이델베르크 파마 리서치 게엠베하 Antibody drug conjugates with cleavable linkers
JP2022538692A (en) * 2019-07-05 2022-09-05 プーレ バイオオーガニクス エスアイエー Synthesis of α-amanitin and its derivatives
EP3792250A1 (en) * 2019-09-13 2021-03-17 Pure Bioorganics SIA Synthesis of alpha-amanitin and its derivatives
AR120218A1 (en) * 2019-10-15 2022-02-02 Heidelberg Pharma Res Gmbh AMATOXIN AND B LYMPHOCYTE SPECIFIC ANTIBODY CONJUGATES
JP2023529455A (en) * 2020-06-09 2023-07-10 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング Methods for synthesizing thioether-containing peptides
KR20230104653A (en) 2020-11-04 2023-07-10 하이델베르크 파마 리서치 게엠베하 A composition comprising a combination of an immune checkpoint inhibitor and an antibody-amatoxin conjugate for use in cancer therapy
US20240024245A1 (en) * 2020-12-22 2024-01-25 Chugai Seiyaku Kabushiki Kaisha Medicine production method including step of freeze-drying with mixed solvent
JP2024512478A (en) 2021-03-19 2024-03-19 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング B lymphocyte-specific amatoxin antibody conjugate
WO2024094688A1 (en) 2022-11-01 2024-05-10 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
EP1859811B1 (en) 2006-05-27 2011-08-24 Faulstich, Heinz, Dr. Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy
CL2009000505A1 (en) 2008-03-05 2010-01-15 Biocryst Pharm Inc Compounds derived from nitrogenous tricycles, inhibitors of viral DNA and RNA polymerases; pharmaceutical composition comprising them; and use in the treatment of viral infections and cancer.
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
EP2416805B1 (en) 2009-04-08 2013-07-24 Heinz Dr. Faulstich Amatoxin antibody conjugates for the treatment of cancer
CA3026727C (en) 2009-04-08 2022-03-22 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
WO2011018611A1 (en) 2009-08-10 2011-02-17 Ucl Business Plc Reversible covalent linkage of functional molecules
BR112012026213B1 (en) 2010-04-15 2021-12-28 Medimmune Limited PYRROLOBENZODIAZEPINE COMPOUNDS, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION INCLUDING CONJUGATE AND USE THEREOF FOR TREATMENT OF A PROLIFERATIVE DISEASE
ES2402254T3 (en) * 2010-09-30 2013-04-30 Heidelberg Pharma Ag Amatoxin conjugates with improved linkers
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
SG11201407017WA (en) 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
JOP20130273B1 (en) 2012-09-11 2021-08-17 Genzyme Corp Glucosylceramide synthase inhibitors
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
JP6438397B2 (en) 2012-09-12 2018-12-12 ジェンザイム・コーポレーション Fc-containing polypeptides with altered glycosylation and reduced effector function
JP6321687B2 (en) * 2014-03-10 2018-05-09 ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング Amatoxin derivatives
EP4115910A1 (en) * 2015-03-09 2023-01-11 Heidelberg Pharma Research GmbH Amatoxin-antibody conjugates
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition

Also Published As

Publication number Publication date
US11590238B2 (en) 2023-02-28
CO2018009533A2 (en) 2018-09-20
HUE059360T2 (en) 2022-11-28
ZA201805336B (en) 2023-09-27
JP2022028756A (en) 2022-02-16
EP3423104A1 (en) 2019-01-09
KR20180114191A (en) 2018-10-17
PT3423104T (en) 2022-08-22
KR102466933B1 (en) 2022-11-11
JP2019511484A (en) 2019-04-25
CL2018002502A1 (en) 2019-02-22
WO2017149077A1 (en) 2017-09-08
US20230233703A1 (en) 2023-07-27
SI3423104T1 (en) 2022-09-30
PL3423104T3 (en) 2022-09-19
RU2018131636A3 (en) 2020-04-08
EP3222292A1 (en) 2017-09-27
JP7362714B2 (en) 2023-10-17
DK3423104T3 (en) 2022-08-29
US20210138081A1 (en) 2021-05-13
JP7084313B2 (en) 2022-06-14
MX2018010247A (en) 2018-12-19
CN108778341B (en) 2022-11-01
BR112018067615A2 (en) 2018-12-26
HRP20220948T1 (en) 2022-10-28
RS63451B1 (en) 2022-08-31
DK3423104T5 (en) 2022-09-05
CA3015138A1 (en) 2017-09-08
CN108778341A (en) 2018-11-09
RU2018131636A (en) 2020-04-03
ES2925006T3 (en) 2022-10-13
AU2017228020A1 (en) 2018-09-06
SG10201913942SA (en) 2020-03-30
AU2017228020B2 (en) 2024-05-16
RU2753416C2 (en) 2021-08-16
NZ745508A (en) 2023-05-26
LT3423104T (en) 2022-08-10
EP3423104B1 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
SG11201807472TA (en) Amanitin conjugates
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201900619XA (en) Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
SG11201908540PA (en) Stable antibody formulation
SG11201909949XA (en) Targeted immunotolerance
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201907034PA (en) Methods of treating influenza
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201408054RA (en) Pegylated oxm variants
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201908660RA (en) N-substituted indole derivatives
SG11201903431SA (en) Sstr-targeted conjugates and particles and formulations thereof
SG11201902567WA (en) Expec glycoconjugate vaccine formulations
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201907693VA (en) Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
SG11201810801QA (en) Brain delivery protein
SG11201900336YA (en) Radioligands for imaging the ido1 enzyme
SG11201811804QA (en) Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors